TruthArchive.ai - Related Video Feed

Since May 2020, Remdesivir has been linked to a 30% death rate among patients receiving the drug for 5 to 10 days in hospitals. In New York, 26.9% of Medicare-aged patients who received Remdesivir died. The Cardiovascular Toxicology Journal found in October 2020 that Remdesivir is cardiotoxic and can cause death of heart cells. Despite this, the FDA and NIH continue to approve and recommend Remdesivir as the only drug for hospitalized COVID-19 patients. The World Health Organization published in April of last year that Remdesivir leads to increased acute kidney failure compared to other drugs. Shockingly, the FDA recently authorized the use of Remdesivir for newborns and children up to 18 years old.

At home, it is recommended to treat viral replication by giving zinc and other remedies like hydroxychloroquine and ivermectin. However, the protocol followed was to provide no treatment until hospitalization. Once in the hospital, the treatment included ventilators and Remdesivir. It is claimed that Tony Fauci knew Remdesivir could be lethal, as it had caused harmful side effects in Ebola patients. The drug was then used in the pandemic, leading to kidney failure, heart failure, and organ collapse in those who died. The deaths were attributed to Remdesivir rather than the virus itself.

From March 2020 to March 2024, 941 people in the military community were administered remdesivir. Of those, 601 died, representing a death rate of 64%. The speaker questions whether remdesivir directly caused the deaths, or if other factors were involved. They also question whether the Department of Defense has been forthcoming with information about this.

At home, it is recommended to treat viral replication by giving remedies like zinc and hydroxychloroquine, ivermectin, which reduce the spread of the disease. However, the protocol followed was different. No treatment was given until hospitalization, where ventilators and Remdesivir were used. It is known that Remdesivir can be harmful, as it caused side effects in Ebola patients. The drug was manipulated and made standard of care, leading to kidney failure, heart failure, and organ collapse in COVID-19 patients. The deaths during the pandemic were often attributed to kidney failure, which was caused by Remdesivir, not the virus itself.

Since May 2020, Remdesivir has been linked to a 30% death rate among patients receiving the drug in hospitals for 5 to 10 days. In New York, 26.9% of Medicare-aged patients who received Remdesivir died. The Cardiovascular Toxicology Journal found in October 2020 that Remdesivir causes heart cell death and is cardiotoxic. However, the FDA and NIH continue to approve and recommend Remdesivir as the only drug for hospitalized COVID-19 patients, despite the World Health Organization's report in April of last year that it causes increased acute kidney failure. Shockingly, the FDA recently authorized the use of Remdesivir for newborns and children up to 18 years old.

A speaker claims remdesivir, an experimental drug, caused COVID-19 patient deaths in hospitals between days one and nine of a ten-day treatment. The speaker states that Dr. Anthony Fauci claimed in May 2020 that remdesivir was found safe and effective in an African drug trial in February 2019, and he hyperlinked the study in a memo to hospitals. The speaker says that the African trial actually showed a 53% death rate, leading the safety board to suspend remdesivir use and notify funders of its toxicity. The speaker alleges that Dr. Fauci and his NIH department funded the Ebola trial in Africa. The speaker accuses Fauci of lying to Congress and the American people by claiming the drug was safe and effective when the safety board deemed it too deadly and toxic.

Since May 2020, remdesivir may result in at least 30% death in hospitalized patients who receive it for five to ten days. CMS data for Medicare patients in New York showed 26.9% of those who received remdesivir died. In October 2020, the cardiovascular toxicology journal found remdesivir causes death of heart cells, is cardiotoxic, and can lead to cardiac arrest. Despite this, in December 2020, the NIH, with Anthony Fauci, updated guidelines listing remdesivir as the only FDA-approved drug for hospitalized Americans, even though the WHO published data in April of last year that it increases acute kidney failure compared to other drugs used to treat COVID-19. As of January 21st of this year, the FDA extended emergency use authorization, making remdesivir the only authorized medication that can be administered intravenously to newborns to 18-year-olds for COVID-19.

Ralph Barrick, the inventor of coronavirus and developer of Remdesivir, a drug used to treat COVID, had a hand in both. However, Remdesivir had a high kill ratio of 53% and was pulled by the World Health Organization for Ebola treatment. Despite this, in 2020, Anthony Fauci and others decided to use Remdesivir on COVID patients, knowing it would cause deaths. This was premeditated murder, with the criminals sitting next to President Donald Trump. There are other individuals involved as well. Efforts are being made by courageous sheriffs and DAs to compile evidence of the deaths caused by Remdesivir and take legal action to end these felonies.

In 2018, remdesivir had a high kill rate in Ebola trials, making it unethical for use in Africa. Despite this, it was chosen in 2020 to treat COVID. The financial interests behind promoting certain drugs during the pandemic raise concerns about justice. The same group linked to eugenics influences these decisions, which is troubling.

In 2011, 2012, and 2014, publications revealed that pseudouridine in mRNA shots could cause rapid cancers. Remdesivir, with a 53% mortality rate, was chosen by the FDA for COVID treatment despite being deemed unethical by the World Health Organization due to high death rates in Africa. This lethal drug was administered regardless of viral load, resulting in unnecessary deaths.

Multiple studies, including one by the WHO, show that Remdesivir actually increases the risk of death. It's concerning that the federal government incentivizes hospitals to prescribe this toxic drug by offering a 20% bonus on the entire hospital bill for Medicare patients. Remdesivir costs around $3,000 per course. On the other hand, Ivermectin, as mentioned by Dr. Kory, reduces the risk of death by about 50%. Unfortunately, clinicians still use the wrong drug, Dexamethasone, in the wrong dose and for the wrong duration of time, simply because the NIH recommends it. The NIH and other agencies have disregarded multiple FDA-approved drugs that are both cost-effective and safe.

Speaker 0: There were four drugs that were being tested for Ebola. Remdesivir killed more people than placebo, and the data safety monitoring board had actually stopped the study where literally fifty three percent of Speaker 1: the patients died in the failed Ebola trial and was repurposed. It was a failed Ebola drug because it caused more harm than good in Ebola trials. It was still unpatent. It was Tony Fauci's drug of choice. The majority of hospital deaths were actually caused by Anthony Fauci because his NIH put out protocols that if the hospital systems adhered to, they got bonuses, big bonuses, lots of money, $3,000 per for putting an IV in of remdesivir. Boom. $3,000. But guess what? On top of the entire hospital stay, a 20% bonus, that could be hundreds of thousands of dollars. Speaker 0: The data was so overwhelming that remdesivir killed patients more so than placebo. The drug had to be stopped, and this was published in the New England Journal in the 2019. Speaker 2: What happened during COVID could not have happened without propaganda and censorship. And how do we overcome that propaganda and censorship? It's primarily through people not being willing to shut up.

At home, it is recommended to treat viral replication by giving zinc and other zinc-enhancing remedies like hydroxychloroquine and Ivermectin. However, the protocol followed by hospitals was to provide no treatment until admission, and then use ventilators and Remdesivir, which were known to be harmful. Tony Fauci was aware of the dangers of Remdesivir, as it caused lethal side effects in Ebola patients. Despite this, he manipulated a study to make Remdesivir the standard of care, resulting in kidney failure, heart failure, and organ collapse in COVID-19 patients. The deaths attributed to the virus were actually caused by Remdesivir.

In 2018, remdesivir was considered unethical for Ebola clinical trials in Africa due to a 53% kill rate, higher than Ebola's typical mortality. Despite this, it was chosen to treat COVID in April and May 2020, with Anthony Fauci and Deborah Burke advocating for its use despite the World Health Organization's ethical concerns. The speaker claims that a conflict of interest exists because the same entities that financially benefit from promoting certain products are declaring the pandemic. These entities are allegedly linked to the Eugenics office at Carnegie Mellon in 1913 and the establishment of the World Health Organization in 1953. The speaker expresses concern about the influence of eugenics on these decisions.

We ended our previous episode with our COVID pyramid, build layer upon layer of lies, deceit, fraud, scandals. Now, by now you’re wondering how so many hospitals, doctors, and health care workers went along with all of the above. We have reached the capstone of our nauseating COVID pyramid. Pyramid. We shall name the capstone M and M, money and murder in hospitals. Shocking as it may sound, we’ve seen it before. Remember the unjust administering the killer drug midazolam in The UK as shown in part 19? Well, The US and many other countries had their own version called remdesivir. Here’s what happened. Hospitals were given incentives, as in money, for each and every COVID casualty. According to whistleblowers, investigative journalists, lawyers, and specialists, Hospitals in The US have been receiving $13,000 for every admitted COVID patient. There have been financial extras for every COVID test, for every positive outcome. If patients were treated with the only prescribed drug, remdesivir, the hospital received yet another bonus: 20% of the entire hospital bill of the patient. Then for every patient put on a ventilator, the hospital received $39,000. And if that patient officially died of COVID nineteen, they got yet another $13,000. That’s a lot of money. According to attorney Thomas Renz and CMS whistleblowers, the hospitals receive approximately $100,000 per COVID casualty if the above protocol was followed. Now the thing is, the American hospitals received this money in advance based on the COVID predictions, based on the flawed models of people like Brooks. If the hospitals didn’t actually meet those models, they had to pay that money back at a later stage. And we’re talking millions of dollars here. So what happened? Everybody who was admitted to a hospital, for instance because of a car accident or because of cancer or diabetes or kidney failure, everybody got a PCR test to start with. Due to the ridiculous amount of cycles, there was an abundance of false positives. False positives equals positives equals COVID patients equals money. Hence, the sunrise in COVID patients. Then remdesivir left its detrimental mark just like midazolam had done in The UK. You see, remdesivir is not a new drug. It was used in 2018 during the West African Ebola outbreak. It was known to have severe adverse effects such as kidney damage, liver damage, and even death. Yet in 2020, Anthony Fauci directed that remdesivir was to be the drug hospitals used to treat COVID nineteen, hence the incentives. So what happened next? Those poor patients only got worse, after which they were put on a ventilator. After all, that was yet another bonus of many thousands of dollars pouring straight into the pockets of the hospitals. Now the problem with ventilators is that the patient is put into an induced coma. His or her breathing is taken over by a machine that puts extra pressure on the lungs called barrow pressure. In the case of damaged lungs due to for instance pneumonia, those lungs will only get worse. The chances of that patient recovering, of being able to be taken off the ventilator and to start breathing by himself are very, very small. Combined with organ failure as a result of remdesivir, the chances of that patient ever leaving the hospital alive are next to nothing.

An experimental drug called remdesivir will be responsible for people's deaths. People diagnosed with COVID-19 in the hospital died between day one and day nine, specifically on day nine of a ten-day remdesivir treatment. Dr. Anthony Fauci claimed in May 2020 that remdesivir was found safe and effective in a drug trial in Africa a year earlier (02/2019), and hyperlinked the study in a memo to hospitals. However, in that trial, remdesivir killed 53% of people, and the safety board suspended its use at month six, deeming it too deadly and toxic for Ebola patients. Dr. Anthony Fauci and his department at the NIH funded the Ebola trial in Africa in 02/2019. Therefore, Fauci lied to Congress and the American people by claiming the drug was safe and effective against Ebola, when the safety board had deemed it too deadly and pulled it from the trial.

To treat viral infections at home, zinc and its enhancers, like hydroxychloroquine and ivermectin, should be used, as they significantly reduce disease spread. However, the established protocol delayed treatment until hospitalization, where patients received ventilators and remdesivir—both potentially lethal. Remdesivir had previously shown harmful effects in Ebola trials, leading to its discontinuation due to a high rate of severe side effects. Despite this, it became standard care during the pandemic, contributing to kidney failure, heart failure, and organ collapse in patients. Many who died were reported to have kidney failure, which was not caused by the virus but rather by the effects of remdesivir.

In 1970, a Japanese biochemist named Satoshi Omorra discovered a bacterium with intriguing effects against roundworm and shared it with American colleague William Campbell of Merck. Campbell used the bacterium to create ivermectin, released by Merck in 1980. Ivermectin proved extremely effective against river blindness (onchocerciasis), a disease caused by a parasitic worm that affected Central and South America and much of Africa. With ivermectin, river blindness has been largely eliminated in the Americas and greatly reduced in Africa. Billions of doses have been administered; it is listed among the World Health Organization’s essential medicines. Merck’s patent expired in 1996; the drug is cheap to produce, globally available in various formulations, and, at normal dosages, has no important side effects. In 2015, Omurra received the Nobel Prize for Medicine, shared with Campbell. Fast forward to early 2020, when the COVID-19 pandemic spread. Scientists searched for drugs with antiviral activity, and Monash University in Australia conducted a literature search that found ivermectin had shown activity against Zika, West Nile, and influenza. They performed experiments and found that ivermectin displays remarkable activity against SARS-CoV-2 in vitro, reporting a 5,000-fold reduction in viral levels after a single treatment without cytotoxicity, and proposed a mechanism for this effect. Around the same time, two American scientists noted that ivermectin was used as prophylaxis against river blindness in Africa and examined whether widespread ivermectin prophylaxis correlated with COVID-19 rates. They found that countries with extensive ivermectin prophylaxis had significantly lower COVID-19 rates. In Miami, Dr. Jean Jacques Reiter, a critical care and pulmonary specialist, treated COVID-19 patients with ivermectin after being urged by a patient’s son. He reported rapid improvement: the patient’s FiO2 requirements declined within 48 hours, and she was discharged within about a week. Reiter treated many patients with ivermectin and published a June 2020 preprint; he later testified before a Senate committee about his experiences. He stated that among hundreds of outpatients treated by his team, only two were admitted to the hospital; neither died or required intubation. Uncontrolled studies on ivermectin as prophylaxis and treatment circulated globally. A daughter described a care-home incident in Ontario, where residents on a floor receiving high-dose ivermectin for scabies reportedly had no COVID-19 infections among residents, even as staff on that floor became infected. In New York, Pierre Corry teamed with Reiter and Paul Merrick to form the Frontline COVID-19 Critical Care Alliance (FLCCC). In October 2020, the FLCCC released the Eye Mask Plus protocol, centering on ivermectin for prevention and treatment, and published a meta-analysis reviewing nine studies on prophylaxis and 12 studies on treatment, including seven randomized trials, all showing ivermectin’s superiority to controls. They presented figures showing reduced mortality and case rates associated with ivermectin use in various regions, including Peru, Mexico (Chiapas), and Argentina (healthcare workers). On December 8, 2020, FLCCC members appeared before a Senate subcommittee, with testimony claiming mountains of data showing ivermectin’s miraculous effectiveness and requesting the NIH to review their data. The transcript asserts widespread suppression of ivermectin information by mainstream media (New York Times, AP), big tech (YouTube, Twitter, Facebook), and the NIH. It alleges the NIH COVID-19 treatment guidelines panel, established in April 2020, largely recommended against early treatment and promoted remdesivir instead, even though remdesivir’s mortality impact was unproven and the World Health Organization advised against its use for improving survival. The panel’s treatment recommendations (as of 01/03/2021) are cited, highlighting monoclonal antibodies for early patients and no other treatments, except for remdesivir for deteriorating patients. Fauci publicly touted remdesivir’s endpoint as time to recovery, with the primary endpoint reportedly changed mid-trial from mortality to time to recovery, raising concerns about impartiality. The transcript traces remdesivir's production by Gilead Sciences and notes financial ties: seven panel members disclosed funding from Gilead; two of the three panel chairs received Gilead support, and Clifford Lane (one co-author on a remdesivir study) was closely connected to the study, with undisclosed ties among other authors. It argues these ties could impact decision-making and bias toward remdesivir over cheaper, repurposed drugs like ivermectin. The narrative then contrasts the U.S. approach with Uttar Pradesh, India, which authorized ivermectin as prophylaxis and treatment in August 2020. In January 2021, Uttar Pradesh reported near-zero COVID-19 deaths, while the United States faced ongoing high mortality, suggesting potential differential outcomes if ivermectin had been broadly authorized. The closing remarks emphasize the suffering caused by COVID-19 and its broad impacts on families and society.

Remdesivir, one of four drugs tested for Ebola, allegedly killed more people than the placebo, leading the Data Safety Monitoring Board to halt the study. According to the transcript, 53% of patients died in the failed Ebola trial, but the drug was repurposed. It is claimed that Remdesivir was Anthony Fauci's drug of choice, and that the NIH protocols, which provided hospitals with bonuses for using remdesivir, caused the majority of hospital deaths. Reportedly, hospitals received $3,000 for each remdesivir IV and a potential 20% bonus. The data allegedly showed that remdesivir killed more patients than the placebo, resulting in the drug trial being stopped. One speaker stated that it is inexplicable that remdesivir became the standard of care, and that doctors seemingly shut off their brains and followed directions from above without questioning the use of remdesivir in every hospitalized patient.

In 2018, remdesivir had a high kill rate in Africa, making it unsuitable for Ebola trials. Yet, in 2020, it became the top choice for treating COVID-19. Despite objections from the World Health Organization, Anthony Fauci and Deborah Birx endorsed its use. The issue lies in allowing those with financial interests to dictate pandemic responses, potentially influenced by eugenics ideologies.

In 2018, remdesivir, described as one of my favorite targets, was deemed too unethical to put into Ebola clinical trials in Africa because it had a fifty-three percent kill rate published in medical journals. The speaker notes that Ebola doesn’t have a fifty-three percent kill rate, yet in April and May 2020 it was chosen to be the drug of choice to treat COVID. The drug was considered too unethical to use in an African clinical trial because it was killing fifty-three percent of the people to whom it was given. The speaker asserts that Anthony Fauci and Deborah Birx were sitting next to the president advocating the use of remdesivir despite the World Health Organization stating it was unethical to use it. The central problem identified is that, as long as the financial interest that dictates which product is promoted is the one making the declaration of the pandemic, there is no possibility for accountability and no possibility for justice. The speaker argues that the decision-making is influenced by a lineage described as having emerged from the Eugenics office, specifically naming Carnegie Mellon in 1913, the same group of people that established the World Health Organization in 1953. The speaker claims that this same group is the one making the current decisions. The speaker asks the audience to consider their feelings about Eugenics and concludes by expressing a problem with it, tying these connections to the governance and promotion of pandemic responses.

Patients were desperate for ivermectin as their loved ones died, but the focus shifted to remdesivir, a previously failed Ebola drug. By November 2020, the World Health Organization advised against its use, citing ineffectiveness and potential kidney and liver damage. The European Society of Critical Care supported this stance. Despite the warnings, the U.S. Health and Human Services incentivized hospitals with a 20% bonus for administering remdesivir, leading to widespread use. It failed to reduce mortality and caused serious injuries, with some patients dying as a result. In May 2022, the WHO reaffirmed its initial decision, stating that remdesivir should never have been used.

Speaker 0: Remember that in 02/2018, remdesivir, one of my favorite targets, remdesivir was too unethical to put into Ebola clinical trials in Africa because it had a fifty three percent kill rate published in medical journals. Ebola doesn't have a fifty three percent kill rate, but it was chosen in April and May 2020 to be the drug of choice to treat COVID. This drug was too unethical to use in an African clinical trial because it was killing fifty three percent of the people that it was given to. And we had Anthony Fauci, Deborah Burke sitting next to the president going, we need to use remdesivir despite the fact that the World Health Organization said it was unethical to use it. Here's the problem. The problem is as long as the financial interest that dictates what product is going to be promoted is the one making the declaration of the pandemic, We have no possibility for accountability. We have no possibility for justice. And what we do is we allow people who were formed out of the Eugenics office, Carnegie Mellon in 1913, that same group of people that were the same group of people that established the World Health Organization in 1953, that same group of people are the ones who are making this decision. And I don't know how you feel about Eugenics, but I have a problem with it.

I've stated since May 2020 that remdesivir will result in at least 30% death in those who receive it in the hospital. I had data pulled for Medicare patients in New York, and found that 26.9% of those who received remdesivir died. As of October 2020, the cardiovascular toxicology journal found that remdesivir causes death of heart cells and can lead to cardiac arrest. Yet, in December, the NIH decided to update all guidelines for treatment drugs allowed for COVID-19, and remdesivir was the only FDA-approved drug for hospitalized Americans, despite the WHO publishing that it causes increased acute kidney failure. As of January of this year, the FDA extended an emergency use authorization, making remdesivir the only authorized medication that can be administered to newborns to 18-year-olds.

Conflicts and controversies surrounding remdesivir are significant. In November 2020, the World Health Organization conducted a comprehensive study and advised against using remdesivir in hospitals due to its association with death and kidney and liver injuries. Despite this, the U.S. incentivizes its use by offering hospitals a 20% bonus on the total bill if remdesivir is administered. As a doctor, I find it troubling that while other medications do not provide such financial incentives, the use of remdesivir can lead to substantial additional costs for hospitals, contradicting the WHO's recommendations. This situation highlights a serious disconnect in medical decision-making.